Skip to content
Dosage GuideResearch Reference

Octreotide Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Octreotide. All information is for educational purposes only.

Quick Answer

Octreotide is administered via subcutaneous injection (Sandostatin) 2–4 times daily or as a long-acting release (LAR) intramuscular injection (Sandostatin LAR Depot) every 4 weeks. Dosage depends on the indication and patient response; titration is required. For acromegaly, initial dose is typically 50 mcg SC three times daily or 20 mg IM every 4 weeks. Carcinoid syndrome may require higher doses.

→ Octreotide Benefits→ Octreotide Side Effects→ Full Octreotide Profile
Table of Contents

Standard Dosage Range

Research dosing range: 50–200 mcg SC 2–4× daily; 10–40 mg IM every 4 weeks (LAR)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Acromegaly

50–200 mcg2–3× daily (SC) or 10–40 mg every 4 weeks (LAR)
Duration

Ongoing; long-term management

Titrate to normalize IGF-1 levels. LAR formulation provides sustained release over 4 weeks. SC injections may be needed for breakthrough symptoms with LAR.

Carcinoid Syndrome

100–500 mcg2–4× daily (SC) or 20–40 mg every 4 weeks (LAR)
Duration

Ongoing; long-term management

Titrate to control flushing and diarrhea. Some patients may require higher doses. SC injections may be needed for breakthrough symptoms with LAR.

Neuroendocrine Tumors (NETs)

20–30 mgEvery 4 weeks (LAR)
Duration

Ongoing; long-term management

For tumor stabilization and progression-free survival. Typically use LAR formulation. Monitor for tumor growth and hormone secretion.

Variceal Bleeding

50 mcgIV bolus, then 50 mcg/hour continuous infusion
Duration

2–5 days

Used in conjunction with endoscopic therapy to reduce portal pressure and control bleeding. Monitor for rebound bleeding after discontinuation.

Refractory Diarrhea

50–200 mcg2–3× daily (SC)
Duration

As needed; intermittent or long-term

For diarrhea unresponsive to other treatments (chemotherapy-induced, AIDS-related, post-surgical). Monitor for side effects and adjust dose accordingly.

Timing & Frequency

SC injections should be administered between meals to minimize gastrointestinal side effects. LAR injections are administered every 4 weeks. Consistent timing is important for maintaining stable drug levels.

Cycle Guidance

Octreotide is typically used as a continuous, long-term therapy for chronic conditions like acromegaly, carcinoid syndrome, and neuroendocrine tumors. There is no need for cycling. Dosage adjustments may be necessary over time based on patient response and disease progression.

Reconstitution Reference

Quick reference for reconstituting Octreotide. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeSandostatin: 50, 100, 500, 1000 mcg/mL vials. Sandostatin LAR Depot: 10, 20, 30 mg vials.
BAC Water VolumeSandostatin LAR Depot requires reconstitution with supplied diluent (2 mL).
Concentration & DrawSandostatin: Varies depending on vial strength. Sandostatin LAR Depot: Varies depending on vial strength and diluent volume.
StorageSandostatin: Refrigerate at 2–8°C. Sandostatin LAR Depot: Refrigerate at 2–8°C before reconstitution. After reconstitution, administer immediately.
StabilitySandostatin: Stable until expiration date when refrigerated. Sandostatin LAR Depot: Reconstituted suspension should be administered immediately; discard any unused portion.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical starting dose of octreotide for acromegaly?
The typical starting dose for acromegaly is 50 mcg subcutaneously three times daily, or 20 mg intramuscularly every 4 weeks (LAR Depot). Dosage is then adjusted based on IGF-1 levels and symptom control.
How long does octreotide LAR Depot last?
Octreotide LAR Depot is a long-acting formulation that is injected intramuscularly every 4 weeks. It provides sustained release of octreotide over this period.
Can octreotide be taken orally?
No, octreotide is not available in oral form. It is administered via subcutaneous injection (Sandostatin) or intramuscular injection (Sandostatin LAR Depot). An oral formulation is in development but not yet approved.

Last updated: 2026-02-19